COVID-19 Update: We are currently shipping orders daily. However, due to transit disruptions in some geographies, deliveries may be delayed. To provide all customers with timely access to content, we are offering 50% off Science and Technology Print & eBook bundle options. Terms & conditions.
Progress in Medicinal Chemistry - 1st Edition - ISBN: 9780128211731, 9780128211748

Progress in Medicinal Chemistry, Volume 59

1st Edition

Editors: David Witty Brian Cox
Hardcover ISBN: 9780128211731
eBook ISBN: 9780128211748
Imprint: Elsevier
Published Date: 5th May 2020
Page Count: 260
Sales tax will be calculated at check-out Price includes VAT/GST
Price includes VAT/GST

Institutional Subscription

Secure Checkout

Personal information is secured with SSL technology.

Free Shipping

Free global shipping
No minimum order.

Table of Contents

    1. Small molecules—Giant leaps for immuno-oncology
    2. Lisa Kötzner, Bayard Huck, Sakshi Garg and Klaus Urbahns

    3. P2X7 receptor antagonists for the treatment of systemic inflammatory disorders
    4. Christine F. Gelin, Anindya Bhattacharya and Michael A. Letavic

    5. Discovery and development of ASK1 inhibitors
    6. Reginald Brys, Karl Gibson, Tanja Poljak, Steven Van Der Plas and David Amantini

    7. An overview of DNA-encoded libraries—A versatile tool for drug discovery

Daniel Madsen, Carlos Azevedo, Iolanda Micco, Lars Kolster Petersen and Nils Jakob Vest Hansen


Progress in Medicinal Chemistry, Volume 59, provides a review of eclectic developments in medicinal G139 chemistry. Each chapter is written by an international board of authors, with this release focusing on Small Molecules - Giant Leaps for Immuno-Oncology, Reviewing P2X7, Reviewing ASK1, and Reviewing DNA-encoded libraries.

Key Features

  • Provides extended, timely reviews of topics in medicinal chemistry
  • Contains targets and technologies relevant to the discovery of tomorrow’s drugs
  • Presents analyses of successful drug discovery programs


Everyone interested in the strategy and practice of the preclinical phases of the creation of new medicines. Those wishing to understand the drivers of drug design or expand their knowledge of therapeutic target classes


No. of pages:
© Elsevier 2020
5th May 2020
Hardcover ISBN:
eBook ISBN:

Ratings and Reviews

About the Editors

David Witty

David Witty

Dr David Witty has more than 20 years experience in the pharmaceutical industry as a medicinal chemist and project leader working principally in areas of anti-infectives, metabolic diseases, cognition and pain, delivering clinical candidates for several conditions. He led IT Strategy within the Neurology division of GSK, developing and deploying the first Electronic Notebooks for drug discovery to sites in the UK and Singapore. He has contributed more than 90 scientific papers, reviews, patents and books on medicinal and synthetic chemistry.

In 2010 David and several colleagues successfully raised $35M in venture funding to found Convergence Pharmaceuticals, a specialist ion channel company focused on the development of novel treatments for pain, based in Cambridge UK. David presently leads their discovery programme and manages scientific operations within the business.

David is chairman of the Fine Chemicals Group of the Society of Chemical Industry, with responsibility for the delivery of conferences, seminars and training courses for chemists throughout the UK and Europe, and advising parliamentary bodies on matters of relevance to the UK chemical industry.

Since 2008 David has been a STEM ambassador for SETPOINT, introducing school students at both primary and secondary level to the excitement and possibilities of pursuing scientific careers, through workshops, lectures and competitions.

Affiliations and Expertise

WITNET LTD, Cambridge, UK

Brian Cox

Professor Brian Cox is at University of Sussex, Brighton, UK

Affiliations and Expertise

University of Sussex, Brighton, UK